Council for Innovation Promotion Urges Biden Admin to Oppose IP Waiver
Notable letter signatories include former
"The WTO's proposal to suspend IP rights for certain Covid-19 technologies would jeopardize the development of these critically important technologies and harm the ability to diagnose and treat Covid-19 patients," said
In October, the U.S. International Trade Commission published a report on the proposed IP waiver and found no evidence that intellectual property protections impeded access to Covid-19 therapeutics and diagnostics.
"IP rights have played a pivotal role in the record-breaking development of Covid-19 vaccines, tests, and therapies from the outset of the pandemic," said
The World Trade Organization will likely decide whether to approve the proposed IP waiver for Covid-19 diagnostics and therapeutics in
"The Council for Innovation Promotion is honored to lead this distinguished group in advocating for the preservation of global IP rights," said
About the Council for Innovation Promotion: The Council for Innovation Promotion is a bipartisan coalition dedicated to promoting strong and effective intellectual property rights that drive innovation, boost economic competitiveness, and improve lives everywhere.
Media contact
[email protected]
202-990-3350
View original content to download multimedia:https://www.prnewswire.com/news-releases/council-for-innovation-promotion-urges-biden-admin-to-oppose-ip-waiver-302006616.html
SOURCE Council for Innovation Promotion
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Civil Rights and Trial Attorney John Gomez Announces Wrongful Death Lawsuit After Developmentally Disabled Man Killed at Fallbrook Care Facility
- Uber Settles Background Check Sexual Assault Case Less Than 48 Hours After Jury Selection
- Trump Coin Price Prediction: A $2.50 Recovery Target Meets Remittix’s $0.46 Final Presale Stage
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share